Prelude Capital Management’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Prelude Capital Management’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-923	Closed	-$55.7K	–	1546
2022 Q4	$55.7K	Buy	923 +93	+11%	+$6.23K	﹤0.01%	1124
2022 Q3	$62K	Sell	830 -222	-21%	-$23.2K	﹤0.01%	1216
2022 Q2	$121K	Buy	+1,052	New	+$123K	﹤0.01%	1393

Other funds holding OMIC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's OMIC Position: Q1 2023 in Review

Prelude Capital Management sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2023, closing a stake of 923 shares — an estimated $55.7K sold.

Prelude Capital Management first reported a position in OMIC in Q2 2022 and held it in 3 quarters. The position peaked at $121K in Q2 2022. 66 funds tracked by Wall St. Rank hold OMIC as of Q1 2023.

Prelude Capital Management reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Prelude Capital Management sold 923 Singular Genomics Systems, Inc. Common Stock shares in Q1 2023, an estimated $55.7K.
Prelude Capital Management first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Prelude Capital Management's Singular Genomics Systems, Inc. Common Stock position peaked at $121K in Q2 2022.
66 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.